Results provide opportunity to expand CLDN18.2 positivity to ≥25% expression, representing approximately 60% of patients in this setting CLARITY-Gastric01...
Growth momentum continues. On track to deliver ambition of $80 billion in Total Revenue in 2030
Monday U.S. Economic Lookahead Durable-goods orders (June) Featured Earnings AstraZeneca ...
Barchart Research What to Expect from AZN Earnings AZN Generated July 24, 2026 Current Price $169.26 EPS Estimate $$2.50 Consensus Rating Strong Buy Average Move 2.07% AstraZeneca's Monday Morning Call...
NEW YORK , July 23, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of AstraZeneca PLC ("AstraZeneca" or the "Company") (NYSE: AZN). Such investors are advised...
The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of AstraZeneca PLC (“AstraZeneca” or “the Company”)...
When it comes to major ETF providers, Schwab might not be first to mind, but they offer up several solid, low-cost products that investors can build around.
AstraZeneca (AZN) shares fell roughly 8% as the market opened on July 9, 2026. Investors who held AZN and lost money are examining whether the losses tied to this collapse may be recoverable.
NEW YORK , July 16, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of AstraZeneca PLC ("AstraZeneca" or the "Company") (NYSE: AZN). Such investors are advised...
Wainua missed its Phase 3 endpoint, hitting Ionis Pharmaceuticals hard while AstraZeneca absorbed the blow easily, boosting rivals BridgeBio, Pfizer and Alnylam Pharmaceuticals.